2 completed. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Porphyria, Acute Intermittent: new trials by email Literature Review of Porphyria, Acute Intermittent trials Research Report on Porphyria, Acute Intermittent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP) Givosiran, Placebo - Acute Hepatic Porphyria, Acute Intermittent Porphyria | Phase 3 | Completed | Alnylam Pharmaceuticals | 94 | 2017-11-16 | 2024-04-22 |
| Porphozym in the Treatment of Acute Attacks in AIP recombinant human porphobilinogen deaminase (Porphozym) - Acute Intermittent Porphyria | Phase 2 / Phase 3 | Completed | Zymenex A/S | 36 | 2003-06-11 | 2018-03-09 |
Coproporphyria, Hereditary (1) · Porphyria, Variegate (1) · Porphyrias (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Digestive System Diseases (2) · Genetic Diseases, Inborn (2) · Liver Diseases (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Porphyrias, Hepatic (2) · Skin Diseases (2) · Skin Diseases, Genetic (2) · Skin and Connective Tissue Diseases (2) · Porphyrias (1)
givosiran (1)
Alnylam Pharmaceuticals (1) · Zymenex A/S (1)
United States (2) · Australia (1) · Bulgaria (1) · Canada (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Italy (1) · Japan (1) · Mexico (1) · Netherlands (1) · Poland (1) · South Korea (1) · Spain (1)
PMID 32521132, PMID 36028858, PMID 37479139, PMID 38044204, PMID 41388232